{"id":966740,"date":"2026-05-26T08:06:42","date_gmt":"2026-05-26T12:06:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/"},"modified":"2026-05-26T08:06:42","modified_gmt":"2026-05-26T12:06:42","slug":"lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","title":{"rendered":"LENZ Therapeutics to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, May  26, 2026  (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of <a href=\"http:\/\/www.vizz.com\" rel=\"nofollow\" target=\"_blank\">VIZZ\u00ae<\/a> (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences:<\/p>\n<p>\n        <strong>William Blair 46<\/strong><br \/>\n        <sup><br \/>\n          <strong>th<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Growth Stock Conference <\/strong><br \/>\n        <br \/>\n        <strong>Date: <\/strong>June 2, 2026<br \/><strong>Location: <\/strong>Chicago, IL<br \/><strong>Format: <\/strong>1&#215;1 investor meetings<\/p>\n<p>\n        <strong>2026 Jefferies Global Healthcare Conference<\/strong><br \/>\n        <br \/>\n        <strong>Date: <\/strong>June 3, 2026<br \/><strong>Location: <\/strong>New York, NY<br \/><strong>Format: <\/strong>1&#215;1 investor meetings<\/p>\n<p>\n        <strong>Goldman Sachs 47<\/strong><br \/>\n        <sup><br \/>\n          <strong>th<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Global Healthcare Conference<\/strong><br \/>\n        <br \/>\n        <strong>Date: <\/strong>June 9, 2026<br \/><strong>Location: <\/strong>Miami, FL<br \/><strong>Format: <\/strong>1&#215;1 investor meetings<\/p>\n<p align=\"justify\">\n        <strong>About LENZ Therapeutics<\/strong><br \/>\n        <br \/>LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ\u00ae (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit <a href=\"http:\/\/www.VIZZ.com\" rel=\"nofollow\" target=\"_blank\">www.VIZZ.com<\/a> and <a href=\"http:\/\/www.LENZ-tx.com\" rel=\"nofollow\" target=\"_blank\">www.LENZ-tx.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Dan Chevallard <br \/>LENZ Therapeutics<br \/><a href=\"mailto:IR@LENZ-Tx.com\" rel=\"nofollow\" target=\"_blank\">IR@LENZ-Tx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTc2NyM3NjE4ODg5IzIyNjM5ODc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2I4YmJkN2QtMGEzNi00ZGZhLTlhYjEtYWY0YWEzNzViYzhhLTEyNzU1MzctMjAyNi0wNS0yNi1lbg==\/tiny\/LENZ-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of VIZZ\u00ae (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: William Blair 46 th Annual Growth Stock Conference Date: June 2, 2026Location: Chicago, ILFormat: 1&#215;1 investor meetings 2026 Jefferies Global Healthcare Conference Date: June 3, 2026Location: New York, NYFormat: 1&#215;1 investor meetings Goldman Sachs 47 th Annual Global Healthcare Conference Date: June 9, 2026Location: Miami, FLFormat: 1&#215;1 investor meetings About LENZ Therapeutics LENZ Therapeutics is a pharmaceutical company focused on the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;LENZ Therapeutics to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-966740","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LENZ Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LENZ Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of VIZZ\u00ae (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: William Blair 46 th Annual Growth Stock Conference Date: June 2, 2026Location: Chicago, ILFormat: 1&#215;1 investor meetings 2026 Jefferies Global Healthcare Conference Date: June 3, 2026Location: New York, NYFormat: 1&#215;1 investor meetings Goldman Sachs 47 th Annual Global Healthcare Conference Date: June 9, 2026Location: Miami, FLFormat: 1&#215;1 investor meetings About LENZ Therapeutics LENZ Therapeutics is a pharmaceutical company focused on the &hellip; Continue reading &quot;LENZ Therapeutics to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-26T12:06:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTc2NyM3NjE4ODg5IzIyNjM5ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LENZ Therapeutics to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-05-26T12:06:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\"},\"wordCount\":203,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNTc2NyM3NjE4ODg5IzIyNjM5ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\",\"name\":\"LENZ Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNTc2NyM3NjE4ODg5IzIyNjM5ODc=\",\"datePublished\":\"2026-05-26T12:06:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNTc2NyM3NjE4ODg5IzIyNjM5ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNTc2NyM3NjE4ODg5IzIyNjM5ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LENZ Therapeutics to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LENZ Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"LENZ Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of VIZZ\u00ae (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: William Blair 46 th Annual Growth Stock Conference Date: June 2, 2026Location: Chicago, ILFormat: 1&#215;1 investor meetings 2026 Jefferies Global Healthcare Conference Date: June 3, 2026Location: New York, NYFormat: 1&#215;1 investor meetings Goldman Sachs 47 th Annual Global Healthcare Conference Date: June 9, 2026Location: Miami, FLFormat: 1&#215;1 investor meetings About LENZ Therapeutics LENZ Therapeutics is a pharmaceutical company focused on the &hellip; Continue reading \"LENZ Therapeutics to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-26T12:06:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTc2NyM3NjE4ODg5IzIyNjM5ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LENZ Therapeutics to Participate in Upcoming Investor Conferences","datePublished":"2026-05-26T12:06:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/"},"wordCount":203,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTc2NyM3NjE4ODg5IzIyNjM5ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","name":"LENZ Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTc2NyM3NjE4ODg5IzIyNjM5ODc=","datePublished":"2026-05-26T12:06:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTc2NyM3NjE4ODg5IzIyNjM5ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTc2NyM3NjE4ODg5IzIyNjM5ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LENZ Therapeutics to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=966740"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966740\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=966740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=966740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=966740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}